Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).
Anas Younes
Consultant or Advisory Role - Millennium; Seattle Genetics
Honoraria - Millennium; Seattle Genetics
John Radford
Consultant or Advisory Role - Millennium
Honoraria - Millennium; Seattle Genetics
Research Funding - Millennium
Stephen Maxted Ansell
No relevant relationships to disclose
Andrea Gallamini
Consultant or Advisory Role - Seattle Genetics
Won Seog Kim
Consultant or Advisory Role - Celltrion
Tatyana A. Feldman
Honoraria - Celgene; Seattle Genetics; Spectrum Pharmaceuticals
Mehdi Hamadani
No relevant relationships to disclose
Jeanenne Chung
Employment or Leadership Position - Millennium
Jingyuan Wang
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Dirk Huebner
Employment or Leadership Position - Millennium
Stock Ownership - Takeda
Joseph M. Connors
Research Funding - Millennium; Seattle Genetics